Drug updated on 4/16/2024
| Dosage Form | Injection (intravenous: 200 mg/20 mL [10 mg/mL]) |
| Drug Class | Influenza virus neuraminidase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than two days.
Summary
- Peramivir (Rapivab) is indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than two days. It has shown superior efficacy in hastening recovery among young and middle-aged adults with seasonal influenza, significantly reducing the time to resumption of usual activities compared to placebo.
- Ten studies provided insights into Rapivab's safety and effectiveness compared with other neuraminidase inhibitors such as baloxavir, laninamivir, oseltamivir, zanamivir.
- In terms of overall effectiveness, peramivir ranked highly in reducing the time to alleviation of symptoms, often outperforming or demonstrating comparable efficacy with other treatments. However, some studies showed that baloxavir might have advantages over peramivir in specific outcomes like fever reduction and viral load decrease.
- The incidence rate of adverse events was relatively similar between patients treated with peramivir versus those treated with other neuraminidase inhibitors, indicating a tolerable safety profile. Baloxavir, however, demonstrated non-significantly reduced adverse events, suggesting it may have a slightly favorable safety profile.
- Both baloxavir and peramivir demonstrated similar safety profiles amongst high-risk patients without significantly increasing adverse event rates, making them suitable options across diverse patient groups, including hospitalized ICU patients suffering from respiratory failure due to influenza where higher doses did not alter outcomes compared to standard treatments.
- Although detailed studies on pediatric populations were not included, the indication for use starting at six months old suggests potential applicability and effectiveness within this critical subgroup, considering their high burden from flu-related illnesses.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Rapivab (peramivir) prescribing information. | 2022 | BioCryst Pharmaceuticals, Inc., Durham, NC |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| 2020-2021 AMMI Canada guidance on the use of antiviral drugs for influenza in the setting of co-circulation of seasonal influenza and SARS-CoV-2 viruses in Canada. | 2020 | Journal of the Association of Medical Microbiology and Infectious Disease Canada |